WallStSmart

IDEXX Laboratories Inc (IDXX)vsENDRA Life Sciences Inc (NDRA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

IDXX leads profitability with a 25.0% profit margin vs 0.0%. IDXX earns a higher WallStSmart Score of 63/100 (C+).

IDXX

Buy

63

out of 100

Grade: C+

Growth: 6.7Profit: 10.0Value: 2.7Quality: 7.0
Piotroski: 6/9Altman Z: 5.92

NDRA

Avoid

25

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 6.5
Piotroski: 3/9Altman Z: -45.23
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

IDXXSignificantly Overvalued (-48.7%)

Margin of Safety

-48.7%

Fair Value

$436.26

Current Price

$504.70

$68.44 premium

UndervaluedFair: $436.26Overvalued

Intrinsic value data unavailable for NDRA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IDXX4 strengths · Avg: 9.8/10
Return on EquityProfitability
70.7%10/10

Every $100 of equity generates 71 in profit

Operating MarginProfitability
35.0%10/10

Strong operational efficiency at 35.0%

Altman Z-ScoreHealth
5.9210/10

Safe zone — low bankruptcy risk

Profit MarginProfitability
25.0%9/10

Keeps 25 of every $100 in revenue as profit

NDRA2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

Areas to Watch

IDXX3 concerns · Avg: 2.7/10
P/E RatioValuation
36.5x4/10

Premium valuation, high expectations priced in

PEG RatioValuation
2.932/10

Expensive relative to growth rate

Price/BookValuation
24.7x2/10

Trading at 24.7x book value

NDRA4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$8.52M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : IDXX

The strongest argument for IDXX centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 25.0% and operating margin at 35.0%.

Bull Case : NDRA

The strongest argument for NDRA centers on Price/Book, Debt/Equity.

Bear Case : IDXX

The primary concerns for IDXX are P/E Ratio, PEG Ratio, Price/Book.

Bear Case : NDRA

The primary concerns for NDRA are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

IDXX profiles as a mature stock while NDRA is a value play — different risk/reward profiles.

IDXX carries more volatility with a beta of 1.54 — expect wider price swings.

IDXX is growing revenue faster at 9.7% — sustainability is the question.

IDXX generates stronger free cash flow (323M), providing more financial flexibility.

Bottom Line

IDXX scores higher overall (63/100 vs 25/100), backed by strong 25.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

IDEXX Laboratories Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.

ENDRA Life Sciences Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

ENDRA Life Sciences Inc. develops technology for clinical diagnostic ultrasound. The company is headquartered in Ann Arbor, Michigan.

Visit Website →

Want to dig deeper into these stocks?